Arpita Lakhotia
Neurology with Special Qualifications in Child Neurology · Owensboro, KYNPI 1407136690
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Novartis Gene Therapies, Inc. (fka Avexis, Inc.) at 37.7% of the total. Reporting peaked in 2019 at $33,327 and has fallen 99.8% since, to $65 in 2025. Among neurology with special qualifications in child neurology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $421.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$15K
- Biogen$13K
- Sarepta Therapeutics, Inc.$5K
- Catalyst Pharmaceuticals, Inc.$5K
- Genentech, Inc.$1K
- Novartis$121
- plus $267 from 7 others
Across 47 payments — averaging $4537.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$92K
- Novartis$70K
- Genentech, Inc.$51K
What the payments were for
- Consulting fees$8,30021%
- Speaking & faculty fees$21,31553%
- Travel & lodging$5,95215%
- Food & beverage$2,9047%
- Education$1,9675%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 28 | $15,250 |
| Biogen | 16 | $13,039 |
| Sarepta Therapeutics, Inc. | 14 | $5,414 |
| Catalyst Pharmaceuticals, Inc. | 14 | $5,004 |
| Genentech, Inc. | 12 | $1,343 |
| Novartis | 1 | $121 |
| Livanova USA, Inc. | 3 | $72 |
| Jazz Pharmaceuticals Inc. | 1 | $65 |
| PTC Therapeutics, Inc. | 3 | $52 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Greenwich Biosciences, Inc. | 1 | $22 |
| ITF Therapeutics LLC | 1 | $21 |
| Aquestive Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,438 in reported general payments places this provider in the 95th percentile of 33 neurology with special qualifications in child neurology providers in Kentucky.
See all neurology with special qualifications in child neurology providers in Kentucky →
Other neurology with special qualifications in child neurology in Owensboro
- Anna EhretOwensboro$1K
- Vinay PuriLouisville$195K
- Gregory BarnesLouisville$12K
- Tarif BakdashLexington$2K
- Darren FarberLouisville$2K
- Zahra HaghighatLexington$2K
- Jaime ShoupLouisville$2K
- David ToupinLexington$1K
- Keisuke UedaLexington$976
- Christopher BartonLouisville$846
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.